Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Part of paid clinical trials in Grand Island, Nebraska.

Sponsor
University of Nebraska
Study ID
NCT00736450
Phase
EARLY_PHASE1
Status
Terminated

Conditions

  • Contiguous Stage II Adult Diffuse Large Cell Lymphoma
  • Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
  • Stage I Adult Diffuse Large Cell Lymphoma
  • Stage III Adult Diffuse Large Cell Lymphoma
  • Stage IV Adult Diffuse Large Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • oblimersen sodium — BIOLOGICAL
    Given IV
  • rituximab — BIOLOGICAL
    Given IV
  • cyclophosphamide — DRUG
    Given IV
  • doxorubicin hydrochloride — DRUG
    Given IV
  • vincristine sulfate — DRUG
    Given IV
  • prednisone — DRUG
    Given orally
  • biopsy — PROCEDURE
    Correlative studies
  • microarray analysis — GENETIC
    Correlative studies
  • immunohistochemistry staining method — OTHER
    Correlative studies
  • gene expression analysis — GENETIC
    Correlative studies
  • cytogenetic analysis — GENETIC
    Correlative studies

Study Details

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oblimersen sodium may help chemotherapy work better by making cancer cells more sensitive to the drugs. Giving oblimersen sodium together with combination chemotherapy may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects of giving oblimersen sodium together with combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage I, stage II, stage III, or stage IV diffuse large B-cell lymphoma

Key Dates

Start date
Jul 23, 2008
Status verified
Oct 2023
Primary completion
Oct 9, 2012
Completion
Oct 9, 2012

Study Design

Enrollment
37 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    See Detailed Description

Primary Outcome Measure

Time to Perform Microarray Study After Receipt of Tissue [ Time Frame: Upto 14 days ]

Locations (2)

FacilityCityStateZIPSite coordinators
Saint Francis Medical CenterGrand IslandNebraska68803-
University of Nebraska Medical CenterOmahaNebraska68198-6805-

Find similar trials in Grand Island, NE

By research site
Saint Francis Medical Center· Grand Island, NEUniversity of Nebraska Medical Center· Omaha, NE